Guanzhang Li

List of Publications by Citations

53 papers	889 citations	13 h-index	29 g-index
56 ext. papers	1,593 ext. citations	5.5 avg, IF	4.2 L-index

#	Paper	IF	Citations
53	Tumor Purity as an Underlying Key Factor in Glioma. *Clinical Cancer Research*, **2017**, 23, 6279-6291	12.9	170
52	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. *OncoImmunology*, **2016**, 5, e1196310	7.2	116
51	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. *Genomics, Proteomics and Bioinformatics*, **2021**, 19, 1-12	6.5	103
50	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. *OncoImmunology*, **2017**, 6, e1328339	7.2	74
49	Clinical practice guidelines for the management of adult diffuse gliomas. *Cancer Letters*, **2021**, 499, 60-72	9.9	61
48	Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. *Cancer Science*, **2018**, 109, 2697-2705	6.9	44
47	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. *Oncotarget*, **2016**, 7, 16384-95	3.3	40
46	ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. *Oncoscience*, **2016**, 3, 258-265	0.8	31
45	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. *Cell Death and Disease*, **2018**, 9, 1190	9.8	27
44	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 439-447	4.9	26
43	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. *Cancer Cell International*, **2018**, 18, 107	6.4	21
42	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. *Cancer Science*, **2020**, 111, 2325-2335	6.9	14
41	CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma. *Oncology Reports*, **2018**, 40, 2036-2046	3.5	14
40	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. *JCI Insight* , **2019**, 5,	9.9	13
39	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. *Frontiers in Immunology*, **2020**, 11, 581209	8.4	10
38	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. *Disease Markers*, **2018**, 2018, 5975216	3.2	8
37	The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. *Clinical Cancer Research*, **2017**, 23, 2177-2185	12.9	8

36	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients		8
35	Redox Regulator Is Associated With Tumor Immunity in Glioma. *Frontiers in Immunology*, **2020**, 11, 580934	8.4	8
34	FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. *Oncotarget*, **2016**, 7, 84587-84593	3.3	8
33	indicates assembly of M0 macrophage and more malignant phenotypes of glioma. *Aging*, **2020**, 12, 8397-8412	5.6	7
32	Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. *Oncologist*, **2021**, 26, e1460-e1469	5.7	6
31	RGS16 promotes glioma progression and serves as a prognostic factor. *CNS Neuroscience and Therapeutics*, **2020**, 26, 791-803	6.8	6
30	Predictive value of MGMT promoter methylation on the survival of TMZ treated -mutant glioblastoma. *Cancer Biology and Medicine*, **2021**, 18, 272-282	5.2	6
29	Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 2079-2086	4	5
28	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. *Aging*, **2018**, 10, 1977-1988	5.6	5
27	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. *Cancer Medicine*, **2020**, 9, 1955-1965	4.8	5
26	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. *Scientific Reports*, **2020**, 10, 16218	4.9	5
25	An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas.. *Brain*, **2022**,	11.2	5
24	Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples. *Cancer Science*, **2021**,	6.9	4
23	ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. *Scientific Reports*, **2020**, 10, 12682	4.9	4
22	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. *Journal of Neurosurgery*, **2021**, 1-9	3.2	4
21	Comparative profiling of immune genes improves the prognoses of lower grade gliomas. *Cancer Biology and Medicine*, **2021**,	5.2	3
20	A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression. *Scientific Reports*, **2020**, 10, 18420	4.9	3
19	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. *OncoTargets and Therapy*, **2021**, 14, 1707-1718	4.4	3

18	A novel methylation signature predicts radiotherapy sensitivity in glioma. *Scientific Reports*, **2020**, 10, 20406	4.9	2
17	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. *CNS Neuroscience and Therapeutics*, **2021**, 27, 617-628	6.8	2
16	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion.. *Frontiers in Immunology*, **2021**, 12, 800928	8.4	2
15	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. *International Journal of Molecular Sciences*, **2022**, 23, 5691	6.3	2
14	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. *Aging*, **2020**, 12, 16155-16171	5.6	1
13	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. *Frontiers in Oncology*, **2021**, 11, 751183	5.3	1
12	High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma. *Chinese Neurosurgical Journal*, **2021**, 7, 22	1.6	1
11	Comprehensive Analysis of the Clinical and Biological Significances of Endoplasmic Reticulum Stress in Diffuse Gliomas. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 619396	5.7	1
10	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. *CNS Neuroscience and Therapeutics*, **2021**, 27, 186-195	6.8	1
9	Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology.. *Biotechnology Journal*, **2022**, e2100693	5.6	1
8	Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells.. *Frontiers in Bioscience*, **2022**, 27, 35		0
7	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. *BMC Neurology*, **2021**, 21, 438	3.1	0
6	Molecular Characterization and Clinical Relevance of in Gliomas 1,018 Chinese Cohort Patients.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 777182	5.7	0
5	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. *Neuro-Oncology Advances*, **2020**, 2, vdaa098	0.9	0
4	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. *Frontiers in Neurology*, **2021**, 12, 682535	4.1	0
3	Functional clustering analysis identifies specific subtypes of aldehyde dehydrogenase associated with glioma immunity.. *Translational Cancer Research*, **2021**, 10, 5052-5064	0.3	0
2	A novel gene signature based on five immune checkpoint genes predicts the survival of glioma. *Chinese Neurosurgical Journal*, **2021**, 7, 15	1.6	
1	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. *Frontiers in Genetics*, **2021**, 12, 741325	4.5	